- Received November 30, -0001
- Accepted November 30, -0001
- Publication August 19, 2020
- Visibility 4 Views
- Downloads 0 Downloads
- DOI 10.18231/j.ijpo.2020.076
-
CrossMark
- Citation
Role of p53 as a prognostic marker in breast carcinoma and its correlation with tumor size, tumor grade and lymph node metastasis
Introduction
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females worldwide, with an estimated 2.08 million cases and 626679 deaths in 2018.[1] Cases are generally high in American and European countries while low in most of Africa and Asia.[2] The international variation in incidence rates is mainly due to reproductive and hormonal factors and early detection.[3] Breast cancer projection for India during time periods 2020 suggests the number to go as high as 1797900.[4]
Early diagnosis and appropriate treatment can prolong the survival of patient diagnosed with breast cancer.[5] The number of cancer-related parameters available to predict the prognosis in breast cancer patients has grown considerably in recent years. Prognostic factors of breast cancer include histological features (histological type, histological grade, lymphovascular invasion), tumor size, lymph node status, steroid hormone receptors status and age.[6], [7], [8] Prognostic and predictive biomarkers including p53 was also identified in breast cancer.
p53 tumor suppressor gene is the most frequently mutated tumor suppressor gene in human malignancy and 30% breast cancers have p53mutation.[9] p53(also known as TP53) is located on chromosome 17p13 and encodes p53 transcription factor. p53 plays a vital role in determining cell fate exposed to DNA damage stimuli.[10] In response to DNA damage, p53 activates p21 and arrests the cells in G1 phase—this constitutes the major G1/S checkpoint. Induction of p53 can also lead to apoptosis by activating pro-apoptotic proteins such as BAX, PUMA, and NOXA.[11]
Unlike normal p53, nonfunctional mutated p53 accumulates in the nucleus of tumor cells, and therefore, it can be detected by immunohistochemical analysis. Multiple studies have shown that p53 over expression in breast cancer is associated with a worse prognosis.[12]
So, aim of this study is to find out role of p53 over-expression in breast carcinoma and its correlation various histological parameters such histological type, tumor grade and lymph node metastasis.
Materials and Methods
The present study was conducted in a tertiary care centre, western U.P. retroprospectively from July 2014 to June 2019. Immuno-histochemical evaluation of a total 50 cases was conducted who were confirmed to have breast carcinoma histologically. The haematoxylin & eosin (H&E) stained slides of the cases were retrieved & screened for confirmation of diagnosis followed by selection of the appropriate paraffin blocks. The representative neoplastic tissue blocks (paraffin embedded) were cut at 3.0µ on poly-L-Lysine coated slides. One of the sections was routinely stained with H&E. The histological grading of the tumor was done on H&E stained sections according to Modified Bloom & Richardson Grading.
Out of 50 patients, 36 patients were of modified radical mastectomy and 14 patients were of lumpectomy. Patient without consent for IHC, inadequate tissue samples, improperly preserved tissues were excluded. Breast carcinoma was used as a positive control. Tumor cells with nuclear staining were accepted as positive. p53 overexpression were taken as Negative, Low, Moderate, High when less than 5%, 5%- 19%, 20% - 50%, >50% of cells were positive for p53. Tumor size was divided into three groups < 20mm, 20 mm– 50mm, >50mm on gross examination.
Descriptive statistical analysis has been carried out in the present study. Chi square test was applied using SPSS version 2.0, p value <0.05 was considered as the minimum level of significance.
Results
In present study, age range of these patients were from 20 to 90 years with mean age 49.5 years. Majority of patients (16/50,32%) were in the age group of 40-49 years. Women of age more than 45 years of age were 32/50(64%). Out of 50 cases, 28(56%) were on the left side and 24(44%) on the right side and no case was found involving both breast. Majority of cases were in upper outer quadrant (24/50,48%) followed by central quadrant (14/50,28%), lower outer(7/50,14%), upper inner(3/50,6%) and lower inner(2/50,4%). Tumor size ranges from 1.5 cm to 15 cm and majority of breast tumors (29/50,58%) were of size >2 cm to 5 cm followed by (15/50,30%) tumors with size >5 cms and least (6/50,12%) were tumor of size ≤ 2.0 cm. In the present study, invasive (infiltrating) carcinoma of no special type was the commonest histological type (41/50,82%) followed by invasive lobular carcinoma (4/50,8%), invasive carcinoma with neuroendocrine differentiation (2/50,4%), metaplastic carcinoma (2/50,4%) and mucinous carcinoma (1/50,2%). All the cases were graded according to Nottingham modification of Bloom Richardson method and majority of the cases were in grade II (21/50,42%) followed by grade I (16/50,32%) and grade III (13/50,26%). According to Nottingham prognostic index, majority of patients were in moderate prognostic group (17/36,47.2%) followed by poor prognostic (12/36,33.3%) and good prognostic group (7/36,19.5%). Out of 36 cases with lymph nodes, 20 cases were positive for metastatic deposits (20/36, 55.55%).
In present study, p53 expression (positive, ≥5%) was seen in (24/50, 48%) cases and rest were negative for p53 expression ([Table 1]). Maximum p53 positivity (≥5%) was seen in invasive breast carcinoma of special type (22/41,53.7%) followed by invasive carcinoma with neuroendocrine differentiation (1/2,50%) and metaplastic carcinoma (1/2,50%). No p53 positivity (<5%) was seen in infiltrating lobular carcinoma and mucinous carcinoma of breast. In cases with tumor size ≤2cm, p53 expression (>5%) was seen in (3/6,50%) cases. In cases of tumor size of >2-5cm, p53 expression (≥5%) was seen in (12/29,41.%) and in tumor size >5 cm, p53 expression(>5%) was seen in (9/15,60%) cases ([Table 2]). Above results was found to be statistically significant (p=0.008917).
9/13(69.2%) of grade III breast tumors were positive for p53 expression (≥5%) followed by grade II breast tumors (10/21,47.6%) and grade I tumors (5/16,31.3%)([Table 3]). Above results were found to be statistically insignificant (p value=0125724). p53 expression was seen maximum in cases with lymph node metastatic deposits (13/20,65%) as compared to lymph node with no metastatic deposits (5/16,31.2%)([Table 4]). Above results was found to be statistically significant (p=0.044171).
| p53 expression | Number of cases (n) | Percentage (%) |
| Negative | 26 | 52 |
| Low positive (5-19%) | 02 | 04 |
| Moderate positive (20-50%) | 14 | 28 |
| High positive (>50%) | 08 | 16 |
| 50 | 100 |
| Tumor size | Number of patients | P53 expression | |||
| <5% | 5-19% | 20-50% | >50% | ||
| ≤2cm | 06 | 3 | 0 | 3 | 0 |
| 2-5cm | 29 | 17 | 2 | 5 | 5 |
| >5cm | 15 | 6 | 0 | 6 | 3 |
| Total | 50 | 26 | 2 | 14 | 8 |
| Tumor grade | Number of patients | p53 expression | |||
| <5% | 5-19% | 20-50% | >50% | ||
| Grade I | 16 | 11 | 1 | 3 | 1 |
| Grade II | 21 | 11 | 1 | 5 | 4 |
| Grade III | 13 | 4 | 0 | 6 | 3 |
| Total | 50 | 26 | 2 | 14 | 8 |
| Lymph node metastasis | Number of patients | p53 expression | |||
| <5% | 5-19% | 20-50% | >50% | ||
| Positive | 20 | 7 | 1 | 5 | 7 |
| Negative | 16 | 11 | 0 | 5 | 0 |
| Total | 36 | 18 | 1 | 10 | 7 |
Discussion
Breast cancer, one of the most common malignancy in women and alone accounts for 25% of all cancer cases and 15% of all cancer deaths among females. In India, breast cancer develops almost a decade earlier than their Western counterparts.[13] Breast cancer is highly heterogeneous disease with a wide range of biological, pathological & clinical characteristics. Role of hormone receptors such as ER/PR & HER-2/neu is well known in treatment of breast cancer whereas new studies has shown the role of p53 in prognosis and overall survival of patients of breast cancer.
In present study, out of total 50 cases, 36(72%) cases were of modified radical mastectomy with lymph nodes and 14 (28%) cases were of lumpectomy.
In present study, majority of cases (16/50, 32%) were in the age group of 40-49 years. The age range of patients ranged from 20 to 90 years with mean age of 49.5 years which is similar to studies done by Nikhra P et al. (2014)[14] and Yadav R et al. (2016).[15] Women of age less than or equal to 45 years were 18/50(36%) and more than 45 years were 32/50(64%) in present study which is similar to study done by Lodha R et al., 2011.[16] Kakarala et al., 2010 [17] in their study found that in Indian population, 16.2% were pre-menopausal, 29.9% were peri-menopausal and 53.9% were post menopausal.
Majority of tumors were on left side 28/50(56%) in comparison to right side 22/50(44%). It has been observed in the past also that breast carcinomas are more common in the left breast than the right. The possible explanations are that the left breast being more bulky and having a larger volume of breast tissue comparatively.[18], [19] Sandhu et al.(2010)[20] and Geethamala et al. (2015)[21] observed the similar findings. The upper outer quadrant, which is the most common site for carcinoma breast according to Sainsbury RC (2004)[22] was the most common site for the tumor with 53.03% of the tumors situated in this location and in the present study also, 24/50(48%) cases were found in upper outer quadrant.
In the present study, tumor size ranges from 1.5 cm to 15 cm and majority of breast tumors (29/50,58%) were of size >2 cm to 5 cm followed by 15/50(28%) tumors with size >5 cms and least (6/50, 12%) were tumor of size ≤ 2.0 cm. Almost similar observations have been reported in other studies such as Sharma M et al (2016),[23] Gupta K et al (2016)12 and Pan Y et al (2017).[9] In India owing to the lack of awareness of this disease and in absence of a breast cancer screening program, the majority of breast cancers are diagnosed at a relatively advanced stage.[16]
The terminology for the most common histological type of breast carcinoma has changed from invasive ductal carcinoma, not otherwise specified (NOS) 2003 to invasive (infiltrating) carcinoma of no special type (NST) 2012.[24] In the present study, invasive carcinoma of no special type was the commonest histological type (41/50, 82%) followed by invasive lobular carcinoma (4/50,8%), invasive carcinoma with neuroendocrine differentiation (2/50,4%), metaplastic carcinoma (2/50,4%) and mucinous carcinoma (1/50,2%). Almost similar results have been reported in the past by various workers Ayadi L et al. (2008),[25] Nikhra et al. (2014), [14] Yadav R et al. (2016), [15] Puvitha RD et al. (2016)[26] and Hashmi AA et al. (2018).[27] Results of the present study were in close proximity to study done by Ayadi L et al. (2008),[25] except for inflammatory carcinoma of breast which is more common in Tunisia and the region of North Africa. On the contrary Nikhra et al. (2014)[14] recorded a higher incidence, 95.34% for infiltrating ductal carcinoma.
All the cases were graded according to Nottingham modification of Bloom Richardson method. In present study, majority of the cases were in grade II (21/50,42%) followed by grade I (16/50,32%) and grade III (13/50,26%). A large number of studies have reported the similar findings such as Ambroise et al., 2011,[19] Puvitha RD et al., 2016 [26] and Pan Y et al., 2017.[9] However, Geethamala K et al. (2015) [21] found grade I (54%) to be more common than other grades in their study.
In the present study, most of breast carcinoma cases were positive for lymph node metastasis (20/36, 55.55%) which is similar to studies done by Azizun-Nisa A et al. (2008),[28] Sharma M et al. (2016)[23] and opposite to study done by Payandeh M et al. (2015).[29]
| p53 expression | Payendah M et al, 201529 (%) | Gupta K et al, 201612 (%) | Pan Y et al, 20179 (%) | Present study (%) |
| Positive | 34 | 88.9 | 73.1 | 48 |
| Negative | 66 | 11.1 | 26.9 | 52 |
The NPI is the most widely accepted prognostic index[30], [31] and developed through multivariate analysis. In clinical practice, three prognostic groups are identified, a good prognostic group with scores less than 3.4, a moderate prognostic group with scores of 3.4-5.4 and a poor prognostic group with score of over 5.4. The respective 15 years survival rates are good, moderate, poor in 80%, 42% and 15% respectively.
In present study, majority of patients were in moderate prognostic group (17/36,47.2%) followed by poor prognostic (12/36,33.3%) and good prognostic group (7/36,19.5%) similar to findings reported by Haybittle JL et al. (1982),[30] Todd JH et al. (1987)[31] and Rolland P et al. (2006).[32]
The p53 gene appears to play a prime role in controlling cell proliferation and apoptosis, and in DNA repair. The genetic changes most commonly found in breast cancer are alterations in the p53 tumor-suppressor gene, withan incidence ranging from 15 to 50% in different series. In present study, p53 over-expression (positive, ≥5%) was seen in (24/50, 48%) cases and rest were negative for p53 expression. Out of overall p53 positive cases, majority of cases show moderate over-expression (14/24, 58.33%) for p53 followed by high over-expression (8/24, 33.34%). Various studies done by Payendah M et al. (2015) [29], Gupta K et al. (2016),[12] Pan Y et al. (2017)[9] also reported p53 over-expression in 34%, 88.9% and 73.1% cases respectively.
In the present study, invasive carcinoma of no special type was the commonest histomorphological type. Maximum p53 over-expression (≥5%) was seen in invasive carcinoma of no special type (22/41,53.7%) followed by invasive carcinoma with neuroendocrine differentiation (1/2,50%) and metaplastic carcinoma (1/2,50%). Infiltrating lobular carcinoma and mucinous carcinoma of breast were negative for p53 expression. The results were found to be statistically insignificant and correlated with other studies done by Golmohammadi R et al, 2012[33] and Kim T et al, 2015.[34] In this study, maximum p53 expression (>5%) was seen in tumor size of more than 5cm (9/15,60%) followed by tumor size ≤2cm (3/6,50%) and >2-5cm (12/29,41%). The results were found to be statistically significant and correlated with other studies done by Rolland P et al., 2007[32] and Hashmi AA et al, 2017.[27] However no statistical correlation was reported by Gupta KK et al., 2016[12] and Pan Y et al., 2017 [9].
In the present study, maximum p53 expression (≥5%) was associated with grade III breast tumors (9/13,69.2%) followed by grade II breast tumors (10/21,47.6%) and grade I tumors (5/16,31.3%). The results were found to be statistically insignificant. These findings correlate with studies done by Pan Y et al (2017)[9] and Hashmi et al (2018).[27] However grade association with p53 was found to be significant in studies done by Yamamoto et al, 2014[33] and Gupta K et al, 2016.[12]
p53 expression (≥5%) was seen maximum in cases with lymph node metastasis (13/20,65%) as compared to lymph node with no metastasis (5/16,31.2%) in present study and above result was found to be statistically significant (p=0.044171). These findings correlate with studies done by Kikuchi S et al., 2013[34] (45%) and Gupta K et al., 2016[12] (98.2%). But according to studies done by Han JS et al. (2011)[35] and Yang P et al. (2013),[36] no significant correlation was found.
Conclusion
In conclusion, we found a statistical significant correlation of p53 expression with tumor size and lymph node metastasis, but no correlation with histological type and tumor grade. However, p53 expression seems to be higher in patients with higher tumor grade. So, breast cancer aggressiveness appears to be directly related to the percentage of p53 positive cancer cells and its over-expression is directly related to histological grade and cell-proliferation fraction. Cases positive for p53 could be interpreted as those which have lost a mechanism for controlling the inhibition of cell proliferation and have gained an activator for malignancy potential. Above findings and correlation with various studies proved that p53 is an independent and poor prognostic factor and can be a potential target for future treatment in breast carcinoma. However, studies need to be carried out on larger scale.
Source of Funding
None.
Conflict of Interest
None.
References
- Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L. Siegel, Lindsey A. Torre, Ahmedin Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2018. [Google Scholar]
- L A Torre, F Bray, R L Siegel, J Ferlay, J Lortet-Tieulent, A Jemal. Global cancer statistics, 2012. Cancer J Clin 2012. [Google Scholar]
- A. Jemal, M. M. Center, C. DeSantis, E. M. Ward. Global Patterns of Cancer Incidence and Mortality Rates and Trends. Cancer Epidemiol Biomark Prev 2010. [Google Scholar]
- S Malvia, S A Bagadi, U S Dubey, S Saxena. Epidemiology of breast cancer in Indian women. Asia-Pac J Clin Oncol 2017. [Google Scholar]
- S Sinha, J Nath. Predictive and Prognostic Factors in Breast Cancer and their Association with ER PR HER2/neu Expression. J Carcinog Mutagenesis 2016. [Google Scholar] [Crossref]
- M Kim, K H Shin, S Y Jung, S Lee, H S Kang, E S Lee. Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer. Cancer Res Treat 2016. [Google Scholar]
- B Pan, R Yao, J Shi, Q Q Xu, Y D Zhou, F Mao. Prognosis of subtypes of the mucinous breast carcinoma in Chinese women: a population-based study of 32-year experience. Oncotarget 2016. [Google Scholar]
- M Y Lee, W J Chang, H S Kim, J Y Lee, S H Lim, J E Lee. Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single Institutional Series. PloS one 2016. [Google Scholar] [Crossref]
- Y Pan, Y Yuan, G Liu, Y Wei. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. PloS one 2017. [Google Scholar]
- A B Williams, B Schumacher. p53 in the DNA-Damage-Repair Process. Cold Spring Harb Perspect Med 2016. [Google Scholar]
- Kang Liu, Naresh Bellam, Hui-Yi Lin, Bing Wang, Cecil R. Stockard, William E. Grizzle. Regulation of p53 by TopBP1: a Potential Mechanism for p53 Inactivation in Cancer. Mol Cell Biol 2009. [Google Scholar]
- K K Gupta, A K Dash, D P Mishra. Correlation of p53 Expression with clinicopathological characteristics of breast carcinoma . Ann Pathol Lab Med 2016. [Google Scholar]
- Gaurav Agarwal, Pooja Ramakant. Breast Cancer Care in India: The Current Scenario and the Challenges for the Future. Breast Care 2008. [Google Scholar]
- P Nikhra, S Patel, D Taviad, S Chaudhary. Study of ER (estrogen receptor), PR (Progesterone Receptor) and HER-2/NEU (Human epidermal growth factor receptor) expression by immunohistochemistry in breast carcinoma. Int J Biomed Adv Res 2014. [Google Scholar]
- R Yadav, R A Sen, P R Chauhan, Er, Pr. HER2/neu status and relation to clinicopathological factors in breast carcinoma. Int J Pharm Pharmaceutical Sci 2016. [Google Scholar]
- R Lodha, D Paul, N Nahar, VK Bhagat, A Joshi, KM Lodha. Association between reproductive factors and breast cancer in an urban set up at central India: A case-control study. Indian J Cancer 2011. [Google Scholar]
- Madhuri Kakarala, Laura Rozek, Michele Cote, Samadhi Liyanage, Dean E Brenner. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysis. BMC Cancer 2010. [Google Scholar]
- H S Andrew Lee. Why is carcinoma of the breast more frequent in the upper outer quadrant?. Breast 2005. [Google Scholar]
- M Ambroise, M Ghosh, V S Mallikarjuna, A Kurian. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev 2011. [Google Scholar]
- DS Sandhu, S Sandhu, RK Karwasra, S Marwah. Profile of breast cancer patients at a tertiary care hospital in north India. Indian J Cancer 2010. [Google Scholar]
- K Geethamala, V Srinivasa Murthy, B R Vani. Hormone receptor expression in breast carcinoma at our hospital: An experience. Clin Cancer Investig J 2015. [Google Scholar]
- R C Sainsbury, R D G Russell, N S Williams, C J K Bulstrode. The breast. Bailey & Love's Short Practice of Surgery 2004. [Google Scholar]
- M Sharma, M Khanna, M Manjari, M Madan, T Singh, T Garg. Immunohistochemical characteristics of Breast Cancer patients with the comparative study of BRCA1, ER, PR, BCL2, P53 and Ki-67 immunohistochemical markers: A population based study. Ann Pathol Lab Med 2016. [Google Scholar]
- S R Lakhani, I O Ellis, S J Schnitt, P H Tan, M J Van De Vijver. World Health Organisation classification of tumors of the breast. Lyon:IARC . [Google Scholar]
- Lobna Ayadi, Abdelmajid Khabir, Habib Amouri, Sondes Karray, Abdallah Dammak, Mohamed Guermazi. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. World J Surg Oncol 2008. [Google Scholar]
- R D Puvitha, S Shifa. Breast carcinoma, receptor status, and HER-2/neu over expression revisited. Int J Sci Study 2016. [Google Scholar]
- Atif Ali Hashmi, Samreen Naz, Shumaila Kanwal Hashmi, Zubaida Fida Hussain, Muhammad Irfan, Erum Yousuf Khan. Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer. BMC Clin Pathol 2018. [Google Scholar]
- Azizun-Nisa By, F Raza, N Kayani. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev 2008. [Google Scholar]
- M Payandeh, R Malayeri, M Sadeghi, E Sadeghi, F Gholami. Expression of p53 and Ki67 in the patients with triple negative breast cancer and invasive ductal carcinoma. Am J Cancer Prev 2015. [Google Scholar]
- J L Haybittle, R W Blamey, C W Elston, J Johnson, P J Doyle, F C Campbell. A prognostic index in primary breast cancer. Br J Cancer 1982. [Google Scholar]
- J H Todd, C Dowle, M R Williams, C W Elston, I O Ellis, C P Hinton. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987. [Google Scholar]
- Phil Rolland, Ian Spendlove, Zahra Madjid, Emad A. Rakha, Poulam Patel, Ian O. Ellis. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer 2007. [Google Scholar]
- Mitsugu Yamamoto, Mitsuchika Hosoda, Kiichiroh Nakano, Shusheng Jia, Kanako C. Hatanaka, Emi Takakuwa. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci 2014. [Google Scholar]
- S Kikuchi, R Nishimura, T Osako, Y Okumura, Y Nishiyama, Y Toyozumi. Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer . Anticancer Res 2013. [Google Scholar]
- Jeong S. Han, Dengfeng Cao, Kyle H. Molberg, Venetia R. Sarode, Roshni Rao, Lisa M. Sutton. Hormone Receptor Status Rather Than HER2 Status Is Significantly Associated With Increased Ki-67 and p53 Expression in Triple-Negative Breast Carcinomas, and High Expression of Ki-67 but Not p53 Is Significantly Associated With Axillary Nodal Metastasis in Triple-Negative and High-Grade Non–Triple-Negative Breast Carcinomas. Am J Clin Pathol 2011. [Google Scholar]
- P Yang, C W Du, M Kwan, S X Liang, G J Zhang. The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis. Sci Rep 2013. [Google Scholar]